PRESS RELEASE
AB SCIENCE ANNOUNCES SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL REPORT
THE COMPANY WILL PUBLISH ITS 2023 ANNUAL FINANCIAL REPORT BY MAY 15, 2024
Paris, April 30, 2024, 6:30 pm CET
AB Science SA (Euronext – FR0010557264 – AB) announced today that it has postponed the publication of its 2023 annual financial report, initially scheduled for April 30, 2024, to give auditors time to complete their audit work.
The Company will publish its 2023 annual financial report by Wednesday, May 15, 2024, following trading.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action is fundamental in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short-term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the company’s lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
More information is available on the AB Science website: www.ab-science.com.
Forward-looking statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.
These forward-looking statements can often be identified by the words “expect,” “anticipate,” “believe,” “intend,” “estimate” or “plan,” as well as other similar terms. Although AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond AB Science’s control and which could imply that the results and Actual events will differ materially from those expressed, implied or anticipated in the forward-looking information and statements. These risks and uncertainties include uncertainties relating to the Company’s product development that may not be successful or marketing authorizations granted by competent authorities or, more generally, any factors that may affect the commercialization ability of products developed by AB Science , as well as those developed or identified in public documents published by AB Science. AB Science disclaims any obligation or undertaking to update forward-looking information and statements, subject to applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.
For additional information, please contact:
AB Science
Financial Communication and Media Relations
investors@ab-science.com
-
Publication CP Décalage Comptes 2023 VEng VF
